| Wissenschaftl. Titel | A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) |
| Erkrankung |
Kinder:
Leukämien und Lymphome:
Rezidiviert/refraktär
|
| Kurzprotokoll | Kurzprotokoll |
erstellt 08.03.2017 Student Studienregister
geändert 27.01.2023 Nicole Wamser